Anti-Hu CD10 Purified

Anti-Hu CD10 Purified
Regulatory status
RUO
Antigen
CD10
Clone
MEM-78
Format
Purified
Reactivity
Human
Application
IP, FC (QC tested)
Variant
0.1 mg
11-209-C100
In stock

0.025 mg
11-209-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG1
Specificity
The antibody MEM-78 reacts with an extracellular epitope CD10 antigen (CALLA - Common acute lymphatic leukemia antigen), a 100 kDa type II integral membrane protein.
Workshop
HLDA IV: WS Code B 506; HLDA V: WS Code B CD10.4
Application
IP, FC (QC tested)
Reactivity
Human
Immunogen
NALM-6 human pre-B cell line
Other names
CALLA, Neprilysin, Neutral endopeptidase, Enkephalinase, Atriopeptidase, MME
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

General references:

Suzuki T, Ino K, Kikkawa F, Uehara C, Kajiyama H, Shibata K, Mizutani S: Neutral endopeptidase/CD10 expression during phorbol ester-induced differentiation of choriocarcinoma cells through the protein kinase C- and extracellular signal-regulated kinase-dependent signalling pathway. Placenta. 2002 Jul;23(6):475-82.
PubMed
Yada K, Kashima K, Daa T, Kitano S, Fujiwara S, Yokoyama S: Expression of CD10 in basal cell carcinoma. Am J Dermatopathol. 2004 Dec;26(6):463-71.
PubMed
Braham H, Trimeche M, Ziadi S, Mestiri S, Mokni M, Amara K, Hachana M, Sriha B, Korbi S: CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression. Virchows Arch. 2006 Aug;449(2):220-4.
PubMed
Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY: Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007 Mar 2;7:3.
PubMed

Product specific references:

Horejsi V, Angelisova P, Bazil V, Kristofova H, Stoyanov S, Stefanova I, Hausner P, Vosecky M, Hilgert I: Monoclonal antibodies against human leucocyte antigens. II. Antibodies against CD45 (T200), CD3 (T3), CD43, CD10 (CALLA), transferrin receptor (T9), a novel broadly expressed 18-kDa antigen (MEM-43) and a novel antigen of restricted expression (MEM-74). Folia Biol (Praha). 1988;34(1):23-34.
PubMed
Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
Angelisová P, Drbal K, Horejsí V, Cerný J: Association of CD10/neutral endopeptidase 24.11 with membrane microdomains rich in glycosylphosphatidylinositol-anchored proteins and Lyn kinase. Blood. 1999 Feb 15;93(4):1437-9.
PubMed
Variant
0.1 mg
11-209-C100
In stock

0.025 mg
11-209-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock